Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2a study of intravenous followed by subcutaneous batoclimab in primary immune thrombocytopenia
CTR20210632Phase 2Active
- Sponsor
- Harbour BioMed
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of batoclimab in immune thrombocytopenia (ITP), sponsored by Harbour BioMed. Started Apr 2021; status: active.
02
Drugs
batoclimab
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on CTR20210632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210632.